Skip to content
In English |
En español
Search
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-25 of 181 for your search:
Cancer Type/Condition:
Acute myeloid leukemia (AML), adult
Stage/Subtype:
adult acute myeloid leukemia in remission
Country:
U.S.A.
Trial Type:
Treatment
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT)
Phase:
Phase IV
Type:
Treatment
Status:
Active
Age:
16 to 65
Sponsor:
Other
Protocol IDs:
MCC-14178
, NCT00361140
2.
Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
4 to 70
Sponsor:
Other
Protocol IDs:
RPCI-RP-9815
, NCI-V99-1527, NCT00003816, RP 98-15
3.
Stem Cell Transplantation for Hematological Malignancies
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
35 and under
Sponsor:
Other
Protocol IDs:
2000LS040
, MT2000-12, 0005M52481, NCT00176839
4.
Efficacy and Safety Study of StemEx®, to Treat Subjects With High Risk Hematologic Malignancies, Following Myeloablative Therapy
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
12 to 55
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
GC P#02.01.001
, NCT00469729
5.
High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
4 and over
Sponsor:
NCI
Protocol IDs:
RPCI-I-72806
, I 72806, NCT00536601
6.
Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
70 and under
Sponsor:
Other
Protocol IDs:
UMN-MT2006-13
, MT2006-13, NCT00630565
7.
Stem Cell Transplant for Hematological Malignancy
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
54 and under
Sponsor:
Other
Protocol IDs:
0107M05202
, MT2001-02, NCT00176930
8.
Chemotherapy With or Without Total-Body Irradiation in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Myelodysplastic Syndromes or Acute Myeloid Leukemia
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
65 and under
Sponsor:
NCI, NHLBI
Protocol IDs:
FHCRC-1992.00
, 6170, NCT00322101, NHLBI-K23-HL084054-01A1
9.
Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
16 to 65
Sponsor:
NCI
Protocol IDs:
CBMTG-0601
, NCT00438958
10.
IV Busulfan With Allo-BMT: Study for Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome
Phase:
Phase III
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
65 and under
Sponsor:
Other
Protocol IDs:
2005-0366
, NCT00469144
11.
Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
50 to 75
Sponsor:
NCI, Other
Protocol IDs:
SU-11122007-874
, 97843, BMT190, NCT00568633, NCT00568633
12.
Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD)
Phase:
Phase III
Type:
Supportive care, Treatment
Status:
Active
Age:
2 to 55
Sponsor:
NCI, NHLBI
Protocol IDs:
385
, BMT CTN 0402, U01 HL069294-05, NCT00406393
13.
Randomized Allogeneic Azacitidine Study
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 to 75
Sponsor:
Other
Protocol IDs:
2008-0503
, NCT00887068
14.
Stem Cell Transplant for Hematologic Diseases and Renal Cell Cancer
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
70 and under
Sponsor:
Other
Protocol IDs:
H8713
, NCT00058825
15.
Infusion of Specially Treated Umbilical Cord Stem Cells After Chemoradiation Treatment for Blood Cancers
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
12 to 60
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
CB001
, NCT00089596
16.
Pentostatin and Donor White Blood Cells in Preventing Graft Rejection in Cancer Patients Who Have Undergone Donor Stem Cell Transplantation
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
Under 75
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
FHCRC-1825.00
, 5605, SUPERGEN-FHCRC-1825.00, NCT00096161
17.
Iodine I 131 Monoclonal Antibody BC8, Fludarabine, Total-Body Irradiation, and Donor Stem Cell Transplant Followed By Cyclosporine and Mycophenolate Mofetil in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndromes
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
16 to 50
Sponsor:
Other
Protocol IDs:
FHCRC-1809.00
, 5602, NCT00119366
18.
Donor Natural Killer Cell Infusion in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Acute Myeloid Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 to 70
Sponsor:
NCI
Protocol IDs:
UMN-2004LS042
, UMN-MT2003-23, UMN-IRB-0405M60481, NCT00303667
19.
Bortezomib Plus Tacrolimus and Methotrexate to Prevent GVHD After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell Transplantation
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
06-065
, X05175, NCT00369226
20.
Alloreactive NK Cells for Allogeneic Stem Cell Transplantation for AML and MDS
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
70 and under
Sponsor:
Other
Protocol IDs:
2005-0508
, NCT00402558
21.
Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
Under 55
Sponsor:
NCI
Protocol IDs:
MSKCC-06125
, NCT00423514
22.
Research Study to Determine if an Experimental Agent, LLME Can Decrease the Incidence and Severity of Graft-Versus-Host-Disease (GVHD) Following Blood (Hematopoietic) Stem Cell Transplantation
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
04U.115
, NCT00429416
23.
Donor Stem Cell Transplant in Treating Patients With Fanconi's Anemia
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
Any age
Sponsor:
NCI
Protocol IDs:
FHCRC-2064.00
, 6294, NCT00453388
24.
Chemotherapy, Donor Stem Cell Transplant, and Graft-Versus-Host Disease Prevention in Treating Patients With Advanced Hematologic Cancer or Other Disease
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 to 69
Sponsor:
NCI
Protocol IDs:
NCI-07-C-0195
, 07-C-0195, NCT00520130
25.
Busulfan, Etoposide, Intensity-Modulated Radiation Therapy, and Stem Cell Transplant in Treating Patients With Advanced Myeloid Cancer
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
2 to 55
Sponsor:
NCI
Protocol IDs:
CHNMC-05013
, 05013, NCT00540995
Select All on Page
1
Help with Results
